Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $580 thousand.

Cash and cash equivalents as of December 31, 2015 were $64.8 million, compared to $49.1 million as of December 31, 2014. The increase is primarily driven by net proceeds from the Company’s public offering of common stock in May 2015 and cash generated from entering into a research collaboration and license agreement with Juno Therapeutics in May 2015, offset by cash used to fund operating activities.

The Company expects 2016 net cash burn to be between $38 million and $42 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.